ACAD
29.24
+0.56
+1.95%
AEMD
2.13
-0.2
-8.58%
APRI
1.16
+0.07
+6.42%
ARNA
14.88
-1.31
-8.09%
ATEC
1.88
+0.02
+1.08%
CNAT
5.1
+0.14
+2.82%
CRXM
0.175
+0.00
+0.1719%
CYTX
1.04
0.00
0.00%
DXCM
77.33
-1.35
-1.72%
GNMK
12.75
+0.1
+0.79%
HALO
14.89
+0.06
+0.40%
ILMN
185.28
+2.29
+1.25%
INNV
0.12
+0.01
+9.55%
INO
8.2
+0.12
+1.49%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
123.87
+0.74
+0.60%
LPTN
2.93
-0.08
-2.66%
MBVX
1.538
+0.068
+4.5918%
MEIP
2.3
+0.14
+6.48%
MNOV
5.54
-0.02
-0.36%
MRTX
3.8
-0.25
-6.17%
MSTX
0.131
-0.007
-5.278%
NBIX
47.35
+0.23
+0.49%
NUVA
76.78
-0.13
-0.17%
ONCS
1.07
-0.07
-6.14%
ONVO
2.76
+0.05
+1.85%
OREX
3.12
+0.03
+0.97%
OTIC
18.75
+1
+5.63%
QDEL
27.38
+0.89
+3.36%
RCPT
231.96
0.00
0.00%
RGLS
0.915
-0.075
-7.576%
RMD
78.44
+0.81
+1.04%
SCIE
0
0.00
0.00%
SPHS
2.06
0.00
0.00%
SRNE
1.85
-0.1
-5.13%
TROV
1.14
-0.16
-12.31%
VICL
2.45
-0.03
-1.21%
VOLC
18
0.00
0.00%
ZGNX
15
0.00
0.00%
ACAD
29.24
+0.56
+1.95%
AEMD
2.13
-0.2
-8.58%
APRI
1.16
+0.07
+6.42%
ARNA
14.88
-1.31
-8.09%
ATEC
1.88
+0.02
+1.08%
CNAT
5.1
+0.14
+2.82%
CRXM
0.175
+0.00
+0.1719%
CYTX
1.04
0.00
0.00%
DXCM
77.33
-1.35
-1.72%
GNMK
12.75
+0.1
+0.79%
HALO
14.89
+0.06
+0.40%
ILMN
185.28
+2.29
+1.25%
INNV
0.12
+0.01
+9.55%
INO
8.2
+0.12
+1.49%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
123.87
+0.74
+0.60%
LPTN
2.93
-0.08
-2.66%
MBVX
1.538
+0.068
+4.5918%
MEIP
2.3
+0.14
+6.48%
MNOV
5.54
-0.02
-0.36%
MRTX
3.8
-0.25
-6.17%
MSTX
0.131
-0.007
-5.278%
NBIX
47.35
+0.23
+0.49%
NUVA
76.78
-0.13
-0.17%
ONCS
1.07
-0.07
-6.14%
ONVO
2.76
+0.05
+1.85%
OREX
3.12
+0.03
+0.97%
OTIC
18.75
+1
+5.63%
QDEL
27.38
+0.89
+3.36%
RCPT
231.96
0.00
0.00%
RGLS
0.915
-0.075
-7.576%
RMD
78.44
+0.81
+1.04%
SCIE
0
0.00
0.00%
SPHS
2.06
0.00
0.00%
SRNE
1.85
-0.1
-5.13%
TROV
1.14
-0.16
-12.31%
VICL
2.45
-0.03
-1.21%
VOLC
18
0.00
0.00%
ZGNX
15
0.00
0.00%
Home » Archive by Category

Xconomy

Still No Official Word From Biopharma Groups About Trump Travel Ban

January 31, 2017 – 4:09 am

Four days after President Donald Trump issued an order to temporarily ban U.S. entry for people from seven Muslim-majority countries—and for all refugees—the drug industry’s two…

[[Click headline to continue reading.]]

Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More

January 27, 2017 – 5:55 am

It was a wild week in biotech and on Capitol Hill. A new study showed it may take another 40 years to achieve gender parity in public biotech boardrooms. Tensions continued to mount between…

[[Click headline to continue reading.]]

Jounce Gets $102M As Biotech IPOs Gain Steam in ’17

January 27, 2017 – 3:44 am

Jounce Therapeutics has gone ahead of its projections and raised roughly $102 million in an IPO, continuing an early, yet successful trend for biotechs trying to go public in 2017. The Cambridge, MA,…

[[Click headline to continue reading.]]

AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut

January 26, 2017 – 9:59 am

AnaptysBio is the first U.S. biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. The San…

[[Click headline to continue reading.]]

Just Four Months After Series A, Delinia Sells to Celgene For $300M

January 26, 2017 – 5:35 am

It didn’t take long for startup Delinia to entice a big drug developer: Just over four months after emerging from stealth and raising a Series A round, the company, developing drugs for a range of…

[[Click headline to continue reading.]]

Inspired by NFL Teammate, Aethlon Seeks Diagnostic for Brain Injuries

January 25, 2017 – 6:56 am

Just as the NFL marketing machine is stoking the build-up to Super Bowl LI, a San Diego diagnostic company headed by a former Denver Broncos player has unveiled plans for a new clinical study of…

[[Click headline to continue reading.]]

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

January 24, 2017 – 10:50 am

One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of…

[[Click headline to continue reading.]]

Report: Biotech VCs Perpetuate Boardroom Gender Gap

January 24, 2017 – 6:39 am

If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame. That’s…

[[Click headline to continue reading.]]

Ex-FDA Commish Califf Gives Props to Patient Groups—With Caveats

January 23, 2017 – 11:40 am

The nation’s former Food and Drug Administration commissioner Robert Califf, appearing for the first time since he resigned last week, told a Silicon Valley crowd this morning that the FDA will…

[[Click headline to continue reading.]]

Bio Roundup: Tom Price, Patient Conflicts, Orphan Games & More

January 20, 2017 – 4:18 am

The new president of the United States, Donald Trump, is being sworn in today amid a storm of questions about the plans that he, and those who might work for him, have in store for American…

[[Click headline to continue reading.]]